Cancer drugs - Revision history

Michael: /* See also */

2018-03-18T15:51:14Z

Michael: wikify

2012-03-29T16:14:43Z

wikify

← Older revision		Revision as of 16:14, 29 March 2012
Line 18:		Line 18:
	\| Herceptin		\| Herceptin
	\| 3345 Euros/month<ref name=spiegel8_8_11_124/>		\| 3345 Euros/month<ref name=spiegel8_8_11_124/>
	\| breast cancer, stomach cancer		\| [[breast cancer]], stomach cancer
	\| notes?		\| notes?
	\|-		\|-
Line 25:		Line 25:
	\| 3496 Euros/month<ref name=spiegel8_8_11_124/>		\| 3496 Euros/month<ref name=spiegel8_8_11_124/>
	\| [[lung cancer]]		\| [[lung cancer]]
	\| EGFR inhibitor - like erlotinib		\| [[EGFR inhibitor]] - like erlotinib
	\|-		\|-
	\| panitumumab		\| panitumumab
	\| Vectibix		\| Vectibix
	\| 3537 Euros/month<ref name=spiegel8_8_11_124/>		\| 3537 Euros/month<ref name=spiegel8_8_11_124/>
	\| indication		\| indication ???
	\| notes?		\| notes?
	\|-		\|-
Line 42:		Line 42:
	\| Femara		\| Femara
	\| 4189 Euros/month<ref name=spiegel8_8_11_124/>		\| 4189 Euros/month<ref name=spiegel8_8_11_124/>
	\| indication		\| indication ???
	\| non-steroidal aromatase inhibitor		\| non-steroidal aromatase inhibitor
	\|-		\|-
Line 49:		Line 49:
	\| 4189 Euros/month<ref name=spiegel8_8_11_124/>		\| 4189 Euros/month<ref name=spiegel8_8_11_124/>
	\| ALL, [[CML]]		\| ALL, [[CML]]
	\| tyrosine kinase inhibitor		\| [[tyrosine kinase inhibitor]]
	\|-		\|-
	\| dasatinib		\| dasatinib
Line 55:		Line 55:
	\| 7513 Euros/month<ref name=spiegel8_8_11_124/>		\| 7513 Euros/month<ref name=spiegel8_8_11_124/>
	\| ALL, CML		\| ALL, CML
	\| tyrosine kinase inhibitor		\| [[tyrosine kinase inhibitor]]
	\|-		\|-
	\| nilotinib		\| nilotinib
	\| Tasigna		\| Tasigna
	\| 5685 Euros/month<ref name=spiegel8_8_11_124/>		\| 5685 Euros/month<ref name=spiegel8_8_11_124/>
	\| CML		\| [[CML]]
	\| tyrosine kinase inhibitor		\| [[tyrosine kinase inhibitor]]
	\|-		\|-
	\| lapatinib		\| lapatinib

Michael: /* Drugs in a table */

2012-01-14T17:09:44Z

Drugs in a table

← Older revision		Revision as of 17:09, 14 January 2012
Line 48:		Line 48:
	\| Gleevec/Glivec		\| Gleevec/Glivec
	\| 4189 Euros/month<ref name=spiegel8_8_11_124/>		\| 4189 Euros/month<ref name=spiegel8_8_11_124/>
	\| ALL, CML		\| ALL, [[CML]]
	\| tyrosine kinase inhibitor		\| tyrosine kinase inhibitor
	\|-		\|-

Michael: /* Drugs in a table */

2011-08-15T02:54:53Z

Drugs in a table

← Older revision		Revision as of 02:54, 15 August 2011
Line 24:		Line 24:
	\| Iressa		\| Iressa
	\| 3496 Euros/month<ref name=spiegel8_8_11_124/>		\| 3496 Euros/month<ref name=spiegel8_8_11_124/>
	\| [[~~Lung~~ cancer]]		\| [[lung cancer]]
	\| EGFR inhibitor - like erlotinib		\| EGFR inhibitor - like erlotinib
	\|-		\|-
Line 51:		Line 51:
	\| tyrosine kinase inhibitor		\| tyrosine kinase inhibitor
	\|-		\|-
	\| ~~non-proprietary name~~		\| dasatinib
	\| Sprycel		\| Sprycel
	\| 7513 Euros/month<ref name=spiegel8_8_11_124/>		\| 7513 Euros/month<ref name=spiegel8_8_11_124/>
	\| ALL, CML		\| ALL, CML
	\| ~~notes?~~		\| tyrosine kinase inhibitor
	\|-		\|-
	\| nilotinib		\| nilotinib

Michael at 02:53, 15 August 2011

2011-08-15T02:53:33Z

← Older revision		Revision as of 02:53, 15 August 2011
Line 21:		Line 21:
	\| notes?		\| notes?
	\|-		\|-
	\| ~~non-proprietary name~~		\| gefitinib
	\| Iressa		\| Iressa
	\| 3496 Euros/month<ref name=spiegel8_8_11_124/>		\| 3496 Euros/month<ref name=spiegel8_8_11_124/>
	\| [[Lung cancer]]		\| [[Lung cancer]]
	\| ~~notes?~~		\| EGFR inhibitor - like erlotinib
	\|-		\|-
	\| panitumumab		\| panitumumab

Michael: /* Drugs in a table */

2011-08-15T02:50:14Z

Drugs in a table

← Older revision		Revision as of 02:50, 15 August 2011
Line 33:		Line 33:
	\| notes?		\| notes?
	\|-		\|-
	\| ~~non-proprietary name~~		\| fulvestrant
	\| Faslodex		\| Faslodex
	\| 719 Euros/month<ref name=spiegel8_8_11_124/>		\| 719 Euros/month<ref name=spiegel8_8_11_124/>
	\| breast cancer		\| breast cancer
	\| ~~notes?~~		\| selective estrogen receptor down-regulator (SERD)
	\|-		\|-
	\| ~~non-proprietary name~~		\| letrozole
	\| Femara		\| Femara
	\| 4189 Euros/month<ref name=spiegel8_8_11_124/>		\| 4189 Euros/month<ref name=spiegel8_8_11_124/>
	\| indication		\| indication
	\| ~~notes?~~		\| non-steroidal aromatase inhibitor
	\|-		\|-
	\| ~~non-proprietary name~~		\| imatinib
	\| Glivec		\| Gleevec/Glivec
	\| 4189 Euros/month<ref name=spiegel8_8_11_124/>		\| 4189 Euros/month<ref name=spiegel8_8_11_124/>
	\| ALL, CML		\| ALL, CML
	\| ~~notes?~~		\| tyrosine kinase inhibitor
	\|-		\|-
	\| non-proprietary name		\| non-proprietary name
Line 57:		Line 57:
	\| notes?		\| notes?
	\|-		\|-
	\| ~~non-proprietary name~~		\| nilotinib
	\| Tasigna		\| Tasigna
	\| 5685 Euros/month<ref name=spiegel8_8_11_124/>		\| 5685 Euros/month<ref name=spiegel8_8_11_124/>
	\| CML		\| CML
	\| ~~notes?~~		\| tyrosine kinase inhibitor
	\|-		\|-
	\| ~~non-proprietary name~~		\| lapatinib
	\| Tyverb		\| Tyverb
	\| 3441 Euros/month<ref name=spiegel8_8_11_124/>		\| 3441 Euros/month<ref name=spiegel8_8_11_124/>
	\| breast cancer		\| breast cancer
	\| ~~notes?~~		\| tyrosine kinase inhibitor / HER2 growth receptor pathway blockade
	\|}		\|}

Michael: create

2011-08-15T02:45:00Z

create

New page

This article covers '''cancer drugs''' from a pathology perspective.

==Drugs in a table==
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto"
! Non-proprietary name
! Trade name
! Cost
! Indication
! Notes
|-
| cetuximab
| Erbitux
| 5267 Euros/month<ref name=spiegel8_8_11_124>{{Citation |last1=Grill |first1=Markus |last2=Hackenbroch |first2=Veronika | year=2011 | editor-last= | editor-first= | title=<nowiki>[Medizin: Das grosse Versprechen]</nowiki> | journal=Der Spiegel | volume= | issue=32 | publication-date=8.8.2011 | pages=124-128 | url= }}</ref>
| stomach cancer, head & neck cancer
| notes?
|-
| trastuzumab
| Herceptin
| 3345 Euros/month<ref name=spiegel8_8_11_124/>
| breast cancer, stomach cancer
| notes?
|-
| non-proprietary name
| Iressa
| 3496 Euros/month<ref name=spiegel8_8_11_124/>
| [[Lung cancer]]
| notes?
|-
| panitumumab
| Vectibix
| 3537 Euros/month<ref name=spiegel8_8_11_124/>
| indication
| notes?
|-
| non-proprietary name
| Faslodex
| 719 Euros/month<ref name=spiegel8_8_11_124/>
| breast cancer
| notes?
|-
| non-proprietary name
| Femara
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| indication
| notes?
|-
| non-proprietary name
| Glivec
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| ALL, CML
| notes?
|-
| non-proprietary name
| Sprycel
| 7513 Euros/month<ref name=spiegel8_8_11_124/>
| ALL, CML
| notes?
|-
| non-proprietary name
| Tasigna
| 5685 Euros/month<ref name=spiegel8_8_11_124/>
| CML
| notes?
|-
| non-proprietary name
| Tyverb
| 3441 Euros/month<ref name=spiegel8_8_11_124/>
| breast cancer
| notes?
|}

==See also==
*[[Cancer]].

==References==
{{Reflist|1}}

[[Category:Clinical]]

← Older revision		Revision as of 15:51, 18 March 2018
Line 72:		Line 72:
	==See also==		==See also==
	*[[Cancer]].		*[[Cancer]].
			*[[Neoadjuvant therapy]].

	==References==		==References==